tiprankstipranks
Trending News
More News >

OncoSil Medical Completes Capital Consolidation to Strengthen Market Position

Story Highlights
OncoSil Medical Completes Capital Consolidation to Strengthen Market Position

Confident Investing Starts Here:

An announcement from OncoSil Medical Ltd ( (AU:OSL) ) is now available.

OncoSil Medical Limited has completed a capital consolidation on a 1 for 400 basis, as approved by shareholders, to streamline its capital structure. This move is part of the company’s strategy to enhance its market position as it continues to commercialize its innovative cancer treatment technology. The consolidation is expected to impact trading, with normal trading on a post-consolidation basis set to commence on June 13, 2025.

More about OncoSil Medical Ltd

OncoSil Medical Limited is a company specializing in the development of cancer treatment devices, particularly the OncoSil™ brachytherapy device. This device is a significant component of a novel brachytherapy treatment for locally advanced unresectable pancreatic cancer, a condition with a poor prognosis and high incidence worldwide. The OncoSil™ device, which delivers targeted intratumoural placement of Phosphorous-32, has received breakthrough device designation in the EU, UK, and US, and is approved for sale in over 30 countries.

Average Trading Volume: 24,333

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$10.94M

See more insights into OSL stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App